{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:41:21Z","timestamp":1790444481738,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04375-2","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:55:31Z","timestamp":1774515331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics, prognostic factors, and feasibility of ICI continuation in immune checkpoint inhibitor-related pneumonitis"],"prefix":"10.1007","volume":"75","author":[{"given":"Keisuke","family":"Masumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Matsukane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Yasukochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotsugu","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayako","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"4375_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"4375_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11:3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y","journal-title":"Nat Commun"},{"key":"4375_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"4375_CR4","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H et al (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2:1607\u20131616. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2453","journal-title":"JAMA Oncol"},{"key":"4375_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM et al (2017) Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35:709\u2013717. https:\/\/doi.org\/10.1200\/JCO.2016.68.2005","journal-title":"J Clin Oncol"},{"key":"4375_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J-E, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"4375_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"4375_CR8","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"4375_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"4375_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1148\/radiol.2015141579","volume":"277","author":"DA Lynch","year":"2015","unstructured":"Lynch DA, Austin JHM, Hogg JC et al (2015) CT-definable subtypes of chronic obstructive pulmonary disease: a statement of the Fleischner Society. Radiology 277:192\u2013205. https:\/\/doi.org\/10.1148\/radiol.2015141579","journal-title":"Radiology"},{"key":"4375_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1148\/radiol.2021203427","volume":"298","author":"T Johkoh","year":"2021","unstructured":"Johkoh T, Lee KS, Nishino M et al (2021) Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology 298:550\u2013566. https:\/\/doi.org\/10.1148\/radiol.2021203427","journal-title":"Radiology"},{"key":"4375_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1164\/rccm.202505-1054ST","volume":"211","author":"AJ Podolanczuk","year":"2025","unstructured":"Podolanczuk AJ, Hunninghake GM, Wilson KC et al (2025) Approach to the evaluation and management of interstitial lung abnormalities: an Official American Thoracic Society Clinical Statement. Am J Respir Crit Care Med 211:1132\u20131155. https:\/\/doi.org\/10.1164\/rccm.202505-1054ST","journal-title":"Am J Respir Crit Care Med"},{"key":"4375_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","volume":"8","author":"H Hatabu","year":"2020","unstructured":"Hatabu H, Hunninghake GM, Richeldi L et al (2020) Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 8:726\u2013737. https:\/\/doi.org\/10.1016\/S2213-2600(20)30168-5","journal-title":"Lancet Respir Med"},{"key":"4375_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM et al (2013) An Official American Thoracic Society\/European Respiratory Society Statement: update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 188:733\u2013748. https:\/\/doi.org\/10.1164\/rccm.201308-1483ST","journal-title":"Am J Respir Crit Care Med"},{"key":"4375_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/1759-7714.13240","volume":"11","author":"H Wang","year":"2020","unstructured":"Wang H, Guo X, Zhou J et al (2020) Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thorac Cancer 11:191\u2013197. https:\/\/doi.org\/10.1111\/1759-7714.13240","journal-title":"Thorac Cancer"},{"key":"4375_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010114","volume":"12","author":"R Matsukane","year":"2024","unstructured":"Matsukane R, Nakamura S, Minami H et al (2024) Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis. J Immunother Cancer 12:e010114. https:\/\/doi.org\/10.1136\/jitc-2024-010114","journal-title":"J Immunother Cancer"},{"key":"4375_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejro.2022.100434","volume":"9","author":"B Gosangi","year":"2022","unstructured":"Gosangi B, McIntosh LJ, Keraliya A et al (2022) Imaging features of toxicities associated with immune checkpoint inhibitors. Eur J Radiol Open 9:100434. https:\/\/doi.org\/10.1016\/j.ejro.2022.100434","journal-title":"Eur J Radiol Open"},{"key":"4375_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006398","volume":"11","author":"J Naidoo","year":"2023","unstructured":"Naidoo J, Murphy C, Atkins MB et al (2023) Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer 11:e006398. https:\/\/doi.org\/10.1136\/jitc-2022-006398","journal-title":"J Immunother Cancer"},{"key":"4375_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107330","volume":"217","author":"D Stahlbaum","year":"2023","unstructured":"Stahlbaum D, Jablonski R, Strek ME, Bestvina CM, Polley MY, Reid P (2023) Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis. Respir Med 217:107330. https:\/\/doi.org\/10.1016\/j.rmed.2023.107330","journal-title":"Respir Med"},{"issue":"1","key":"4375_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/s12885-022-09642-w","volume":"22","author":"Y Uchida","year":"2022","unstructured":"Uchida Y, Kinose D, Nagatani Y et al (2022) Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors. BMC Cancer 22(1):551. https:\/\/doi.org\/10.1186\/s12885-022-09642-w","journal-title":"BMC Cancer"},{"issue":"6","key":"4375_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6(6):865\u2013871. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"},{"issue":"9","key":"4375_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot J-M, Voisin A-L et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5(9):1310\u20131317. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"},{"key":"4375_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1527690","volume":"15","author":"G Wu","year":"2025","unstructured":"Wu G, Qu J, Zheng J et al (2025) Immunotherapy rechallenge after ICI-related pneumonitis in lung cancer patients: a retrospective cohort study. Front Oncol 15:1527690. https:\/\/doi.org\/10.3389\/fonc.2025.1527690","journal-title":"Front Oncol"},{"issue":"1","key":"4375_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30676-y","volume":"13","author":"D Fujimoto","year":"2023","unstructured":"Fujimoto D, Miura S, Tomii K et al (2023) Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer. Sci Rep 13(1):3698. https:\/\/doi.org\/10.1038\/s41598-023-30676-y","journal-title":"Sci Rep"},{"key":"4375_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lungcan.2018.10.001","volume":"125","author":"T Yamaguchi","year":"2018","unstructured":"Yamaguchi T, Shimizu J, Hasegawa T et al (2018) Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer 125:212\u2013217. https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.001","journal-title":"Lung Cancer"},{"key":"4375_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.resinv.2019.05.002","volume":"57","author":"Y Nakanishi","year":"2019","unstructured":"Nakanishi Y, Masuda T, Yamaguchi K et al (2019) Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig 57:451\u2013459. https:\/\/doi.org\/10.1016\/j.resinv.2019.05.002","journal-title":"Respir Investig"},{"issue":"3","key":"4375_CR27","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","volume":"14","author":"K Suresh","year":"2019","unstructured":"Suresh K, Psoter KJ, Voong KR et al (2019) Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol 14(3):494\u2013502. https:\/\/doi.org\/10.1016\/j.jtho.2018.11.016","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04375-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:55:32Z","timestamp":1774515332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04375-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4375"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04375-2","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"123"}}